ClinicalTrials.gg
CompletedNCT01448057Updated Mar 3, 2017Results posted

Evaluation of Efficacy and Safety of Tablets of Paracetamol, Dimethindene Maleate and Phenylephrine Hydrochloride in Reducing Symptoms of Common Cold and Flu

A Phase 3 interventional study of Paracetamol (500 mg)/dimethindene maleate (1 mg)/ phenylephrine hydrochloride (10 mg) tablets and Paracetamol (500 mg) tablets in Upper Respiratory Tract Infection, Nasal Congestion and Rhinorrhea, sponsored by Novartis. Completed at 6 sites in Brazil. Open to participants aged 18 Years to 65 Years. Per ClinicalTrials.gov, last updated 2017-03-03.

Primary conditionCommon ColdRegistry: Respiratory Tract InfectionsReclassifiedWhy we changed it
Registry
Respiratory Tract Infections — the first condition term the registry derived for this study.
ClinicalTrials.gg
Common Cold
Why
  1. The study's title name Common Cold, a narrower term within Respiratory Tract Infections.
Confidence
High: the new condition is named in the study's own title. Of 46 hand-checked studies reclassified this way, 72% were exactly right and 89% in the right disease family; the registry's first term was right for 4% (measured 2026-10-21). How we classify →
Wrong?
Tell us the study's main condition →

Sponsored by Novartis · Phase 3, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 3
Study type
Interventional
Enrollment
341
Allocation
Randomized
Ages
18 Years to 65 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-19

Among 12 studies in Common Cold with a site in Brazil — 1 open to participants now, 1 under way, 1 of them phase 3. Common Cold · Brazil.

Enrollment
4th of 12
341 · median 183
Started
2013
the only one that year
Phase 3
11 of 12
1 open now
Registered
7th of 12
by date
Lead sponsor
1 of 12
Novartis

Among the 12 studies in Common Cold with a site in Brazil, this one is the 4th largest by enrollment, is the only one that started in 2013, is one of 11 in phase 3, and was the 7th registered.

Common Cold

219 studies on the registry are indexed under Common Cold; 23 are open to participants now.

Browse Common Cold studies →

Open to participants now

1 of the 12 studies in Common Cold with a site in Brazil is open now. Recruiting first, the newest first:

A study can be open while its sites in Brazil have not opened yet or have stopped. Only those recruiting at a site in Brazil →

Who these studies take

Of the 14 Common Cold studies recruiting now, 4 (29%) set no upper age limit and 9 (64%) stop at 75 or younger; 4 take children under 18; 7 take healthy volunteers.

This study: 18 Years to 65 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 12 studies in Common Cold with a site in Brazil, or all of them as a file.
02

Study summary

The study is a clinical evaluation of an over the counter (OTC) combination product containing paracetamol (500 mg), dimethindene maleate (1 mg), phenylephrine hydrochloride (10 mg) compared to paracetamol (500 mg) alone in the treatment of nasal congestion, rhinorrhea, sneezing and other symptoms due to upper respiratory tract infection (URTI).

03

Conditions studied

  • Upper Respiratory Tract Infection
  • Nasal Congestion
  • Rhinorrhea
  • Sneezing

Keywords

  • Paracetamol
  • dimethindene maleate
  • phenylephrine hydrochloride
  • cold and flu symptoms
04

In context

Common Cold Reclassified

219 studies on the registry are indexed under Common Cold; 23 are open to participants now.

This study's enrollment of 341 is above the median of 150 across 184 interventional studies indexed under Common Cold.

Browse Common Cold studies →

Lead sponsor

Novartis is the lead sponsor of 714 studies on the registry; none are open to participants now.

Compared within Common Cold, this study's primary condition as ClinicalTrials.gg classifies it; the registry's first condition term is Respiratory Tract Infections. The counts are of registry records indexed under each term, refreshed daily. How we classify →

05

Who can participate

Ages eligible
18 Years to 65 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • acute URTI, diagnosed by a health care professional at the study site, with the following symptoms having started within 72 hours before the screening/baseline Visit: nasal congestion, sneezing, and rhinorrhea.

Exclusion criteria

  • Use of other drugs within 30 days or 10 half-lives before enrollment, whichever is longer.

    • History of or known to any of the study drugs, or to drugs of similar chemical classes.

Other protocol-defined inclusion/exclusion criteria may apply

Terms in these criteria, in plain language(3)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

Hypersensitivity

An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.

Excipients

The other ingredients in a medicine besides the active drug, such as fillers, colors or preservatives.

06

Study design

Phase
Phase 3
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Single (Investigator)
Enrollment
341 participants (actual)

Study arms

  • Experimental
    Combination Product

    Paracetamol (500 mg)/dimethindene maleate (1 mg)/ phenylephrine hydrochloride (10 mg) tablets

    Drug: Paracetamol (500 mg)/dimethindene maleate (1 mg)/ phenylephrine hydrochloride (10 mg) tablets

  • Active comparator
    Paracetamol tablets

    Paracetamol (500 mg) tablets

    Drug: Paracetamol (500 mg) tablets

Interventions

07

What researchers measure

Primary outcomes

  1. Physician Global Evaluation of Effectiveness on Nasal Symptoms

    The Physician will measure the reduction of Nasal Symptoms (Nasal Congestion, Sneezing, and Rhinorrhea) on day 2. Range from 1 to 5 where 1 is excellent and 5 is bad : 1 = excellent : 75% to 100% remission of signs and symptoms 5 = bad : exacerbation of nasal symptoms

    Time frame: Day 2

Secondary outcomes

  1. Daily Average of the Sum of a 100 mm Visual Analog Scale for All Symptoms

    Subject will assess Nasal and non Nasal symptoms using a 100 mm Visual Analog Scale for each symptom, 0=no symptoms 100= the worst possible symptoms

    Time frame: Day 3

08

Results

Posted Jan 13, 2017

Participant flow

Participant flow — Overall Study
MilestoneCombination ProductParacetamol Tablets
Started170171
Completed162167
Not completed84
Withdrew: Protocol violation32
Withdrew: Lost to follow-up30
Withdrew: Adverse event02
Withdrew: Withdrawal by subject20

Outcome measures

PrimaryPhysician Global Evaluation of Effectiveness on Nasal Symptoms

The Physician will measure the reduction of Nasal Symptoms (Nasal Congestion, Sneezing, and Rhinorrhea) on day 2. Range from 1 to 5 where 1 is excellent and 5 is bad : 1 = excellent : 75% to 100% remission of signs and symptoms 5 = bad : exacerbation of nasal symptoms

Time frame:
Day 2
Reported as:
Mean · score on a scale
Physician Global Evaluation of Effectiveness on Nasal Symptoms
score on a scaleArm AArm B
Physician Global Evaluation of Effectiveness on Nasal Symptoms1.9 ± 0.842.1 ± 0.91
SecondaryDaily Average of the Sum of a 100 mm Visual Analog Scale for All Symptoms

Subject will assess Nasal and non Nasal symptoms using a 100 mm Visual Analog Scale for each symptom, 0=no symptoms 100= the worst possible symptoms

Time frame:
Day 3
Reported as:
Mean · mm
Daily Average of the Sum of a 100 mm Visual Analog Scale for All Symptoms
mmArm AArm B
Daily Average of the Sum of a 100 mm Visual Analog Scale for All Symptoms169.2 ± 231.14225.3 ± 262.59

Adverse events

Collected over 3 days. Non-serious events are listed at a 3% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
Arm A—0/170 (0%)77/170 (45.3%)
Arm B—0/171 (0%)39/171 (22.8%)
Most frequent other events
Most frequent other events
EventArm AArm B
somnolenceNervous system disorders71/17037/171
Abdominal painGastrointestinal disorders6/1702/171

Baseline characteristics

Age, Categorical
Age, Categorical(Participants)Arm AArm BTotal
<=18 years000
Between 18 and 65 years170171341
>=65 years000
Age, Continuous
Age, Continuous(years)Arm AArm BTotal
Mean36 ± 11.6434.5 ± 11.7635.3 ± 11.71
Gender
Gender(Participants)Arm AArm BTotal
Female122134256
Male483785
Region of Enrollment
Region of Enrollment(participants)Arm AArm BTotal
Brazil170171341
09

Study locations

6 sites
  • Santa Casa De Misericordia De Belo Horizonte - Avenida Francisco Sales 1111, Santa Efigenia
    Belo Horizonte/MG, 30150-221, Brazil
  • Sociedade Campineira De Educacao E Instrucao - Rodovia Dom Pedro I, KM 136 Parque das Universidades
    Campinas/SP, Brazil
  • Instituto de Ensino e Pesquisa Clínica do Ceará, Rua Coronel Jucá, 1952 - Dionísio Torres -
    Fortaleza/CE, 60170-320, Brazil
  • Polonio Clinica De Servicios Medicos EM Gastroenterologia E Cirurgia Toracica S/S LTDA - ME, Rua Major Alfredo Servulo de Oliveira Romao, 103, Chacara Braz Miraglia
    Jau/SP, 17210-070, Brazil
  • Associacao Fundo De Incentivo A Pesquisa - AFIP - Rua Marselhesa 500 - Vila Clementino
    Sao Paulo, Brazil
  • : Lal Clinica Centro de Pesquisa e Desenvolvimento Ltda, Rua General Osório, 503, Vila Martina / Valinhos
    São Paulo, 13271-130, Brazil
10

Timeline

Tracking since Sep 25, 2026
Not marked actual or estimatedDates not marked actual or estimated

The record gives a start of Jul 2013, a primary completion of Aug 2015 and a completion of Aug 2015. It does not say whether these dates are actual or estimated.

Results were first posted in Jan 2017, 1 year 5 months after primary completion.

How these figures are worked out, and which studies are left out of them.

Registered
Oct 5, 2011
First posted
Oct 7, 2011
Start
Jul 2013
Primary completionActual
Aug 2015
CompletionActual
Aug 2015
Results first posted
Jan 13, 2017
Last update
Mar 3, 2017
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Mar 3, 2017, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
11

Registry details

Key details

Study ID
NCT01448057
Lead sponsor
Novartis
Responsible party
Sponsor
First posted
Oct 7, 2011
Start date
Jul 2013
Primary completion
Aug 2015
Completion
Aug 2015
Results posted
Jan 13, 2017
Last update
Mar 3, 2017

Oversight

Data monitoring committee
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Jan 2017. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drugs tested here: Acetaminophen · Dimethindene · Phenylephrine

Start the discussion